JP2017524725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524725A5 JP2017524725A5 JP2017514958A JP2017514958A JP2017524725A5 JP 2017524725 A5 JP2017524725 A5 JP 2017524725A5 JP 2017514958 A JP2017514958 A JP 2017514958A JP 2017514958 A JP2017514958 A JP 2017514958A JP 2017524725 A5 JP2017524725 A5 JP 2017524725A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 18
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 15
- 102000048770 human CD276 Human genes 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 101710185679 CD276 antigen Proteins 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000003365 immunocytochemistry Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000013390 scatchard method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004605P | 2014-05-29 | 2014-05-29 | |
| US62/004,605 | 2014-05-29 | ||
| US201462082681P | 2014-11-21 | 2014-11-21 | |
| US62/082,681 | 2014-11-21 | ||
| PCT/EP2015/061777 WO2015181267A1 (en) | 2014-05-29 | 2015-05-28 | Anti-b7-h3 antibodies and diagnostic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524725A JP2017524725A (ja) | 2017-08-31 |
| JP2017524725A5 true JP2017524725A5 (enExample) | 2018-07-12 |
| JP6636016B2 JP6636016B2 (ja) | 2020-01-29 |
Family
ID=53267378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514958A Active JP6636016B2 (ja) | 2014-05-29 | 2015-05-28 | 抗ｂ７−ｈ３抗体及びその診断用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10501544B2 (enExample) |
| EP (1) | EP3149040A1 (enExample) |
| JP (1) | JP6636016B2 (enExample) |
| AU (1) | AU2015265976B2 (enExample) |
| CA (1) | CA2947660C (enExample) |
| WO (1) | WO2015181267A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6636016B2 (ja) * | 2014-05-29 | 2020-01-29 | スプリング バイオサイエンス コーポレーション | 抗ｂ７−ｈ３抗体及びその診断用途 |
| EP3468993A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| WO2018177393A1 (zh) * | 2017-03-31 | 2018-10-04 | 江苏恒瑞医药股份有限公司 | B7-h3抗体、其抗原结合片段及其医药用途 |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| WO2020051275A1 (en) * | 2018-09-05 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against endotrophin and the use thereof |
| TW202028246A (zh) * | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | B7h3單域抗體及其治療性組合物 |
| WO2020102779A1 (en) | 2018-11-16 | 2020-05-22 | Albert Einstein College Of Medicine | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF |
| CN109851673B (zh) * | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2021052307A1 (zh) * | 2019-09-16 | 2021-03-25 | 南京圣和药业股份有限公司 | 一种抗b7-h3抗体及其应用 |
| CN110642948B (zh) | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN113754766A (zh) * | 2020-06-02 | 2021-12-07 | 明慧医药（上海）有限公司 | 抗b7-h3抗体及其制备和应用 |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP2024508081A (ja) | 2021-02-09 | 2024-02-22 | メディリンク セラピューティクス（スーチョウ）カンパニー，リミティド | 生物活性物質コンジュゲート、その調製方法及びその使用 |
| US20240158505A1 (en) * | 2021-03-26 | 2024-05-16 | Theranotics Co., Ltd. | B7-h3 antibody or antigen-binding fragment thereof, and use thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20250230244A1 (en) * | 2021-10-05 | 2025-07-17 | Board Of Regents, The University Of Texas System | Methods and compositions comprising b7-h3 binding polypetides |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN114380910B (zh) * | 2022-01-07 | 2023-04-28 | 苏州旭光科星抗体生物科技有限公司 | 靶向人b7-h3分子的人源化单克隆抗体及其应用 |
| WO2023155808A1 (zh) | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
| WO2023177232A1 (ko) * | 2022-03-18 | 2023-09-21 | 세종대학교산학협력단 | 항 b7-h3 단일클론항체 및 이의 용도 |
| EP4527415A1 (en) | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| CN114773477B (zh) * | 2022-06-23 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗b7-h3抗体及其用途 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024163499A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | Antibodies with selectivity for the 4ig isoform of b7-h3 and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060154313A1 (en) * | 2000-04-13 | 2006-07-13 | Immunex Corporation | Human B7 polypeptide B7-H3A |
| CA2463464A1 (en) * | 2003-04-28 | 2004-10-28 | Auckland Uniservices Limited | Methods of treatment and compositions therefor |
| ES2259270B1 (es) * | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| WO2010096734A2 (en) * | 2009-02-20 | 2010-08-26 | John Wayne Cancer Institute | B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients |
| CN101959216B (zh) | 2009-07-20 | 2014-06-18 | 电信科学技术研究院 | 一种分载波配置增强cell_fach的方法、系统和设备 |
| BR112012022210B1 (pt) * | 2010-03-04 | 2021-08-17 | Macrogenics, Inc | Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| EP2606353A4 (en) * | 2010-08-18 | 2014-10-15 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASES |
| DK2703486T3 (en) * | 2011-04-25 | 2018-05-28 | Daiichi Sankyo Co Ltd | ANTI-B7-H3 ANTIBODY |
| JP6636016B2 (ja) * | 2014-05-29 | 2020-01-29 | スプリング バイオサイエンス コーポレーション | 抗ｂ７−ｈ３抗体及びその診断用途 |
-
2015
- 2015-05-28 JP JP2017514958A patent/JP6636016B2/ja active Active
- 2015-05-28 EP EP15724692.7A patent/EP3149040A1/en not_active Withdrawn
- 2015-05-28 WO PCT/EP2015/061777 patent/WO2015181267A1/en not_active Ceased
- 2015-05-28 AU AU2015265976A patent/AU2015265976B2/en active Active
- 2015-05-28 CA CA2947660A patent/CA2947660C/en active Active
-
2016
- 2016-11-29 US US15/363,992 patent/US10501544B2/en active Active
-
2019
- 2019-10-28 US US16/665,359 patent/US11525003B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524725A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| RU2010117018A (ru) | Антитела к gdf8 и их применения | |
| JP2015533788A5 (enExample) | ||
| RU2015103228A (ru) | Антитела против тау | |
| RU2015155552A (ru) | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника | |
| AU2015265976A1 (en) | Anti-B7-H3 antibodies and diagnostic uses thereof | |
| CN113891746A (zh) | 焦谷氨酸淀粉样蛋白-β的抗体及其用途 | |
| JP2016500659A5 (enExample) | ||
| JP7557023B2 (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| JP2016516008A5 (enExample) | ||
| JP2018527895A5 (enExample) | ||
| JP2017524362A5 (enExample) | ||
| JP2018515071A5 (enExample) | ||
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| JP2018520366A5 (enExample) | ||
| CN121219584A (zh) | 针对nr1的自身抗体的检测 | |
| US12449421B1 (en) | Anti-CD79B protein monoclonal antibody, products containing the same, and uses thereof | |
| US20230242636A1 (en) | Monoclonal antibodies targeted to human taxilin alpha and methods for use of same | |
| KR102688094B1 (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 | |
| CA3016098C (en) | Clinical assessment of m-protein response in multiple myeloma | |
| WO2025107037A1 (en) | Aminopeptidase antibodies | |
| WO2020010304A2 (en) | BCl-2 Antibodies and Immunoassay for Diagnosis of Cancer | |
| WO2014073653A1 (ja) | 腎炎の病変部位の検査方法およびそのための試薬 |